

# AvMed

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

**Drug Requested:** Myalept® (metreleptin)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member AvMed #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight: \_\_\_\_\_ Date: \_\_\_\_\_

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**INITIATION AND CONTINUATION OF TREATMENT – All boxes below must be checked to qualify.**

- Member has a leptin deficiency as defined as **(a copy of fasting laboratory leptin assay results is required for approval):**
  - <4.0 ng/mL fasting leptin for females
  - <3.0 ng/mL fasting leptin for males
- Member has a diagnosis of **(choose indication):**
  - Acquired generalized lipodystrophy
  - Congenital generalized lipodystrophy

(Continued on next page)

- Member has a concurrent condition of:
  - Diabetes mellitus or insulin resistance and failed 30-day trial of (submit chart notes):
    - Metformin, total daily dose of: \_\_\_\_\_

**AND**

- High-dose insulin or insulin pump
- Hypertriglyceridemia and failed 30-day trial of (submit chart notes):
  - Low-fat diet and/or dietary restrictions

**AND**

- Fenofibrate or fenofibrate derivative

**OR**

- Niacin or omega-3 fatty acid

**OR**

- Atorvastatin, simvastatin, pravastatin, rosuvastatin

**OR**

- Other therapy of (please specify): \_\_\_\_\_

INITIATION OF TREATMENT (submit all labs)	<u>REAUTHORIZATION</u> (submit all labs)
HbA1c%	HbA1c%
Fasting glucose _____ mg/dL	Fasting glucose _____ mg/dL
Triglyceride _____ mg/dL	Triglyceride _____ mg/dL
Patient weight _____ kg	Patient weight _____ kg
	Has member experienced clinical improvement or metabolic stabilization while using this medication? (submit chart notes to verify response) <input type="checkbox"/> Yes <input type="checkbox"/> No

If approved, response to initial treatment will be **assessed after 4 months**, then **quarterly reassessment** will be required for continued approval.

**Medication being provided by Specialty Pharmacy - PropriumRx**

**\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\***  
**\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\***